Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IRON - Disc Medicine Inc


IEX Last Trade
50.81
2.010   3.956%

Share volume: 171,793
Last Updated: Fri 30 Aug 2024 09:59:30 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$48.80
2.01
4.12%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
2.85%
1 Month
18.10%
3 Months
46.75%
6 Months
-21.98%
1 Year
-7.08%
2 Year
3,116.46%
Key data
Stock price
$50.81
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$25.60 - $77.60
52 WEEK CHANGE
-$0.03
MARKET CAP 
1.511 B
YIELD 
N/A
SHARES OUTSTANDING 
29.726 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$142,051
AVERAGE 30 VOLUME 
$169,513
Company detail
CEO:
Region: US
Website:
Employees: 52
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.

Recent news